Non-hormonal options for the relief of menopausal disorders

Woman’s nature is unique. Taking into account some historical milestones, it can be noted that the role of women in society has undergone large-scale changes. The woman took a confident position in society. Its main function remains unchanged and it consists in procreation and procreation. A woman’s activity is consistent with the work of her reproductive system (RS). The gradual decrease, and then the cessation of the work of the ovaries, contributes to the life order and health of the fair sex. Menopause is a natural stage in a woman’s life, which corresponds to the peak of social self-realization. However, in some cases, hormonal changes characteristic of this period can serve as a favorable background for the formation of a number of pathological changes. The growing estrogen deficiency is becoming a pathogenetic impetus for the development of a wide range of climacteric disorders. Vasomotor symptoms and hyperhidrosis are the most frequent companions of women during the perimenopausal transition and early postmenopause. Maintaining optimal activity and the full quality of life of patients should be the goal of correcting the negative manifestations of estrogen deficiency and the complications associated with it. Compensating for estrogen deficiency with menopausal hormone therapy (HRT) is the benchmark for menopausal problems. However, there are a number of patients who have contraindications to prescribing HRT or who refuse to receive it for some reason. For this category of patients, alternative methods of diet correction. Combinations of plant extracts with vitamins and minerals have been successfully used in clinical practice for a long time. The article will provide information on the most studied phytoestrogens contained in soy.

1. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1568. https://doi.org/10.1210/jc.2011-3362.

2. Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B.; the Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539. https://doi.org/10.1001/ jamainternmed.2014.8063.

3. Zeleke B., Bell R., Billah B., Davis S. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. Fertil Steril. 2016;105:149–155. https://doi.org/10.1016/j.fertnstert.2015.09.017.

4. Biglia N., Cagnacci A., Gambacciani M., Lello S. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306–312. https://doi.org/10.1080/1369 7137.2017.1315089.

5. Baber R.J., Panay N., Fenton A.; the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy Climacteric. 2016;19(2):109–150. https://doi.org/10.3109/13697137.2015.1129166.

6. Yakushevskaya O.V. Possibilities of using phytoestrogens in the treatment of menopausal syndrome. Meditsinskiy sovet = Medical Council. 2020;(13): 99–104. (In Russ.) https://doi.org/10.21518/2079-701X-2020-13-99-104.

7. Yakushevskaya O.V. Menopausal disorders: effective ways of correction. Moscow; 2017. 50 p. (In Russ.) Available at: https://menopace.ru/static/core/pdf/1%20%D0%9C%D0%B5%D0%BD%D0%BE%D0%BF%D0%B0%D1 %83%D0%B7%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B5%20 %D1%80%D0%B0%D1%81%D1%81%D1%82%D1%80%D0%BE%D0%B8%C C%86%D1%81%D1%82%D0%B2%D0%B0%20%D1%8D%D1%84%D1%84% D0%B5%D0%BA%D1%82%D0%B8%D0%B2%D0%BD%D1%8B%D0 %B5%20%D0%BF%D1%83%D1%82%D0%B8%20%D0%BA%D0%BE%D1%8 0%D1%80%D0%B5%D0%BA%D1%86%D0%B8%D0%B8.pdf.

8. Kolátorová L., Lapčík O., Stárka L. Phytoestrogens and the intestinal microbiome. Physiol Res. 2018;67:401–408. https://doi.org/10.33549/physiolres.934022.

9. Landete J.M., Gaya P., Rodríguez E., Langa S., Peirotén A., Medina M., Arqués J.L. Probiotic Bacteria for Healthier Aging: Immunomodulation and Metabolism of Phytoestrogens. Biomed Res Int. 2017;2017:5939818. https://doi.org/10.1155/2017/5939818.

10. Choi E.J., Kim G.H. The antioxidant activity of daidzein metabolites, Odesmethylangolensin and equol, in HepG2 cells. Mol Med Rep. 2014;9(1):328–332. https://doi.org/10.3892/mmr.2013.1752.

11. Wei X.J., Wu J., Ni Y.D., Lu L.Z., Zhao R.Q. Antioxidant effect of a phytoestrogen equol on cultured muscle cells of embryonic broilers. In Vitro Cell Dev Biol Anim. 2011;47(10):735–741. https://doi.org/10.1007/ s11626-011-9464-x.

12. Mayo B., Vázquez L., Flórez A. B. Equol: A Bacterial Metabolite from The Daidzein Isoflavone and Its Presumed Beneficial Health Effects. Nutrients. 2019;11(9):2231. https://doi.org/10.3390/nu11092231.

13. Křížová L., Dadáková K., Kašparovská J., Kašparovský T. Isoflavones. Molecules. 2019;24(6):1076. https://doi.org/10.3390/molecules24061076.

14. Setchell K.D.R. The history and basic science development of soy isoflavones. Menopause. 2017;24(12):1338–1350. https://doi.org/1097/ GME.0000000000001018.

15. Alfa H.H., Arroo R.R.J. Over 3 decades of research on dietary flavonoid antioxidants and cancer prevention: What have we achieved? Phytochem Rev. 2019;18:989–1004. https://doi.org/10.1007/s11101-019-09632-0.

16. Desmawati D., Sulastri D. Phytoestrogens and their health effect. Open Access Maced. J Med Sci. 2019;7(3):495–499. Available at: https://pubmed. ncbi.nlm.nih.gov/30834024.

17. Poluzzi E., Piccinni C., Raschi E., Rampa A. Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective. Current Medicinal Chemistry. 2014;21(4):417–436. https://doi.org/10.2174/09298673113206660297.

18. Ohmichi M., Tasaka K. Molecular mechanism of action of Selective Estrogen Receptor Modulator in target tissues. J Endocr. 2005;52(2):161–167. https://doi.org/10.1507/endocrj.52.161.

19. Jungbauer А., Medjakovic S. Phytoestrogens and the metabolic syndrome. J Steroid Biochem Mol Biol. 2014;139:277–289. https://doi.org/10.1016/j. jsbmb.2012.12.009.

20. Kuryłowicz A., Cąkała-Jakimowicz M., Puzianowska-Kuźnicka M. Targeting abdominal obesity and its complications with dietary phytoestrogens. Nutrients. 2020;12(2):582. https://doi.org/10.3390/nu12020582.

21. Mueller M., Jungbauer A. Red clover extract: A putative source for simultaneous treatment of menopausal disorders and the metabolic syndrome. Menopause. 2008;15(6):1120–1131. https://doi.org/10.1097/ gme.0b013e31817062ce.

22. Zaydieva Y.Z. Alternative therapy of menopausal disorders in women of climacterical age (literature review). RMJ. Woman and Child Health. 2017;(12):873–878. (In Russ.) Available at: https://www.rmj.ru/articles/ ginekologiya/Alyternativnaya_terapiya_menopauzalynyh_rasstroystv_u_ ghenschin_v_klimakterii.

23. Squadrito F. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med. 2003;114:470–476. https://doi.org/10.1016/s0002-9343(03)00059-7.

24. Squadrito F. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis. 2002;163(2):339–347. https://doi.org/10.1016/s0021-9150(02)00013-8.

25. Khamoshina M.B., Bril’ Yu.A. Menopausal disorders: therapeutic approach variability. News Bulletin. Moscow: Status praesens profmedia; 2014. 19 p. (In Russ.)

26. Chen M.-N., Lin C.-C., Liu C.-F. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic Review. Climacteric. 2015;18:260–269. https://doi.org/10.3109/13697137.2014.966241.

27. Cancellieri F., De Leo V., Genazzani A.D., Nappi C., Parenti G.L., Polatti F. et al. Eficacy on menopausal neurovegetative symptoms and some plasma lipids blood levels of an herbal product containing isoflavones and other plant extracts. Maturitas. 2007;56(3):249–256. https://doi. org/10.1016/j.maturitas.2006.07.001.

28. Cheng G., Wilczek B., Warner M., Gustafsson J.-A., Landgren B.M. Isoflavone treatment for acute menopausal symptoms. Menopause. 2007;14:468–473. https://doi.org/10.1097/GME.0b013e31802cc7d0.

29. Yarmolinskaya M.I., Tarasova M.A. Effectiveness of phytoestrogens implementation in treatment of climacteric syndrome in women with uterine myoma. Zhurnal akusherstva i zhenskikh bolezney = Journal of Obstetrics and Women’s Diseases. 2009;58(1):71–77. (In Russ.) Available at: https://cyberleninka.ru/article/n/effektivnost-fitoestrogenov-v-lecheniiklimaktericheskogo-sindroma.

30. Kaari C., Haidar M.A., Soares Jr. J.M., Nunes M.G., de Azevedo Quadros L.G., Kemp C. et al. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. Maturitas. 2006;53(1):49–58. https://doi.org/10.1016/j.maturitas.2005.02.009.

31. Blumenthal M. Herbal Medicine: Expanded Commision E Monographs. Newton, MA: Integrative Medicine Communications; 2003.

32. Kuznetsova I.V. Phytoestrogens in treatment of menopausal disorders. Gynecology. 2012;14(6):20–23. (In Russ.) Available at: https://medi.ru/info/7750.

33. Unfer V., Casini M.L., Costabile L., Mignosa M., Gerli S., Di Renzo G.C. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004;82:145–148. https://doi.org/10.1016/j.fertnstert.2003.11.041.

34. Jargin S.V. Soy and phytoestrogens: possible side effects. Ger Med Sci. 2014;12:18. Available at: https://pubmed.ncbi.nlm.nih.gov/25587246.

35. Bilal I., Chowdhury A., Davidson J., Whitehead S. Phytoestrogens and prevention of breast cancer: The contentious debate. World J Clin Oncol. 2014;5(4):705–712. https://doi.org/10.5306/wjco.v5.i4.705.

36. Smirnova T.V., Bril’ Yu.A. Phytoestrogens and cancer prevention. The protective effect of isoflavones on the mammary gland. News bulletin. Moscow: Status praesens profmedia; 2016, рр. 1–13. (In Russ.) Available at: https://old.praesens.ru/fitoestrogeny-i-onkoprofilaktika.

37. Zeng M., Zhang L., Li M., Zhang B. Estrogenic Effects of the Extracts from the Chinese Yam (Dioscorea opposite Thunb.) and Its Effective Compounds in Vitro and in Vivo. Molecules. 2018;23(2):11. https://doi. org/10.3390/molecules23020011.

38. Kuznetsova I.V., Voichenko N.A., Kirillova M.Yu. Quality of life and cardiovascular risk in women during menopausal transition and postmenopause. Meditsinskiy alfavit = Medical Alphabet. 2020;(4):39–45. (In Russ.) https://doi.org/10.33667/2078-5631-2020-4-39-45.

39. Kargozar R., Azizi H., Salari R. A review of effective herbal medicines in controlling menopausal symptoms. Electron Physician. 2017;9(11): 5826–5833. https://doi.org/10.19082/5826.

40. Vysotskaya I.V., Letyagin V.P. Pharmacological effects and molecular mechanisms of action of a herbal medicine based on Vitex agnuscastus. Opuholi ženskoj reproduktivnoj sistemy = Tumors of Female Reproductive System. 2017;13(1):14–19. (In Russ.) https://doi. org/10.17650/1994-4098-2017-13-1-14-19.

41. Emamzadeh F., Word B., Cotton E., Hawkins A. Modulation of Estrogen alpha and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro. Anticancer Res. 2020;40(7):3669–3683. https://doi.org/10.21873/anticanres.14356.

42. Fusaro M., Gallieni M., Rizzo M.A., Stucchi A. Vitamin K plasma levels determination in human health. Clin Chem Lab Med. 20171;55(6):789–799. https://doi.org/10.1515/cclm-2016-0783.

43. Ali F., Hosmane N.S., Zhu Y. Boron Chemistry for Medical Applications. Molecules. 2020;25(4):828. https://doi.org/10.3390/molecules25040828.